TheraRadar
← Back
Data updated: Jun 28, 2026

CONCORD BIOTECH LTD

Generics

CONCORD BIOTECH LTD is a generic drug manufacturer focused on Neurology.

2019
Since
5
Drugs
-
Trials
0
New Drugs (2yr)

CONCORD BIOTECH LTD's Key Drugs

CONCORD BIOTECH LTD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

CONCORD BIOTECH LTD's Recent FDA Approvals

New NDA/BLA approvals for CONCORD BIOTECH LTD over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

CONCORD BIOTECH LTD's Therapeutic Areas

CONCORD BIOTECH LTD's approved drugs and pipeline span 1 therapeutic area, led by Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 100%
1 drugs

CONCORD BIOTECH LTD's Top Competitors

CONCORD BIOTECH LTD's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

CONCORD BIOTECH LTD Pipeline Snapshot

Active clinical trials for CONCORD BIOTECH LTD across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling